Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe
In line with results from other studies, the SC form of daratumumab had less impact on patients' emotional burden than the IV form.
Authors
- Xavier Guillaume (ORCID: https://orcid.org/0009-0006-1882-3349)
- Kate Morgan (ORCID: https://orcid.org/0000-0002-2592-1012)
- Julien Thévenon (ORCID: https://orcid.org/0000-0001-9271-3961)
- Marjorie Leclerc (ORCID: https://orcid.org/0000-0002-7489-8058)
- Claire Graziani-Taugeron (ORCID: https://orcid.org/0009-0002-2951-4702)
- Valeria Magarotto (ORCID: https://orcid.org/0009-0003-1079-7121)
- Bleuenn Rault (ORCID: https://orcid.org/0000-0003-0423-2899)
- Wafae Iraqi
- Silene ten Seldam
- Dahbia Horchi
Institutions
- Oracle (United States) (US)
- Janssen (France) (FR)
- European Federation of Allergy and Airways Diseases Patients Associations (BE)
- Janssen (Italy) (IT)
Publication Details
- Journal
- Patient Preference and Adherence
- Published
- 2024-09-01
- DOI
- https://doi.org/10.2147/ppa.s453920
- Citations
- 2
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Janssen Pharmaceuticals